- Home
- CDTX vs OLMA Comparison
CDTX vs OLMA Comparison
Compare CDTX & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTX
- OLMA
- Stock Information
- Founded
- CDTX 2012
- OLMA 2006
- Country
- CDTX United States
- OLMA United States
- Employees
- CDTX N/A
- OLMA N/A
- Industry
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- CDTX Health Care
- OLMA Health Care
- Exchange
- CDTX Nasdaq
- OLMA Nasdaq
- Market Cap
- CDTX 259.0M
- OLMA 289.0M
- IPO Year
- CDTX 2015
- OLMA 2020
- Fundamental
- Price
- CDTX $17.82
- OLMA $3.36
- Analyst Decision
- CDTX Strong Buy
- OLMA Strong Buy
- Analyst Count
- CDTX 8
- OLMA 4
- Target Price
- CDTX $38.00
- OLMA $26.75
- AVG Volume (30 Days)
- CDTX 156.0K
- OLMA 1.0M
- Earning Date
- CDTX 05-14-2025
- OLMA 03-18-2025
- Dividend Yield
- CDTX N/A
- OLMA N/A
- EPS Growth
- CDTX N/A
- OLMA N/A
- EPS
- CDTX N/A
- OLMA N/A
- Revenue
- CDTX $1,275,000.00
- OLMA N/A
- Revenue This Year
- CDTX N/A
- OLMA N/A
- Revenue Next Year
- CDTX N/A
- OLMA N/A
- P/E Ratio
- CDTX N/A
- OLMA N/A
- Revenue Growth
- CDTX N/A
- OLMA N/A
- 52 Week Low
- CDTX $10.00
- OLMA $3.15
- 52 Week High
- CDTX $28.42
- OLMA $16.62
- Technical
- Relative Strength Index (RSI)
- CDTX 33.85
- OLMA 25.80
- Support Level
- CDTX $19.83
- OLMA $3.93
- Resistance Level
- CDTX $23.76
- OLMA $4.26
- Average True Range (ATR)
- CDTX 1.58
- OLMA 0.34
- MACD
- CDTX -0.53
- OLMA -0.06
- Stochastic Oscillator
- CDTX 5.11
- OLMA 12.81
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.